Henry Ford Hospital, Rosetta Genomics To Develop MicroRNA-Based Diagnostics For Brain Cancer

Armen Hareyan's picture

Brain Cancer

Rosetta Genomics, Henry Ford Health System to develop microRNA-based diagnostics and prognostics for brain cancer. The Henry Ford Hospital is one of the world's leading research centers for brain cancer.


Under the collaboration, the parties will conduct a genome-wide molecular analysis of human brain cancer tumors to identify unique microRNA biomarkers that have diagnostic and prognostic potential. Upon receipt of the results from this analysis, Rosetta Genomics will use its proprietary microRNA extraction technologies to perform a microRNA analysis from Formalin Fixed Paraffin Embedded (FFPE) samples received from Henry Ford Hospital.

"The goal of our collaborations with the leading cancer research centers is to seek new indications for our microRNA-based diagnostics," said Amir Avniel, President and CEO of Rosetta Genomics. "Together with Henry Ford Hopsital's leading brain cancer researchers, we believe we will be able to leverage the potential microRNAs hold as biomarkers to develop diagnostic and prognostic tools for this difficult disease."

"There is great unmet medical need for improved diagnostics in identifying and treating patients with brain cancer," said Chaya Brodie, Ph.D., and Tom Mikkelsen, M.D. of the department of neurosurgery at Henry Ford Hospital. Dr. Brodie is Director of the William and Karen Davidson Laboratory of Cell Signaling & Tumorigenes and neuro-oncologist Dr. Mikkelsen is co-director of the Hermelin Brain Tumor Center. "A significant advantage of using microRNAs as biomarkers, is that they do not degrade when the tumor sample is stored as an FFPE block. As FFPE blocks can be stored at room temperature, these sample types are readily available and allow us to conduct retrospective studies. Through these studies, we can identify microRNA diagnostic and prognostic biomarkers, such as for disease staging, response to treatment, and risk of recurrence. Combining Rosetta Genomics' proprietary technologies for microRNA research and its experience in this field with our expertise in brain cancer is a good starting point for this important project."